Resmetirom
Stock Recap #PipelineProspector

Pipeline Prospector March 2024: FDA approves pathbreaking NASH drug from Madrigal, two meds for PAH

March was clearly a month of drug approvals, as the US Food and Drug Administration (FDA) went on a

Pipeline Prospector 2023 highlights: Obesity drugs perk up Lilly, Novo sales; ADCs spur dealmaking

The year 2023 was marked by volatility. The good news is that despite factors like inflation, intere

Pipeline Prospector Nov 2023: Lilly, Novo post sharp rise in Q3 sales; AbbVie buys ImmunoGen for US$ 10.1 billion

Through much of 2023, markets remained volatile, with pharma indices managing to inch up only in som

Biotech indices inch up post SVB bloodbath; Covid drugmakers report drop in Q1 sales

In March, the collapse of Silicon Valley Bank (SVB) had dragged the biotech indices down. SVB had ma

Pipeline Prospector Dec 2022: Biotech indices fall on close of a volatile year

The year 2022 was a difficult one for the biotech sector. Marked with geopolitical unrest, rising in